60.22
+2.52
+(4.37%)
At close: April 11 at 4:00:01 PM EDT
60.99
+0.77
+(1.28%)
After hours: April 11 at 7:57:10 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
1,015,324
1,015,324
829,253
660,116
443,310
Cost of Revenue
159,417
159,417
192,361
139,304
81,413
Gross Profit
855,907
855,907
636,892
520,812
361,897
Operating Expense
304,432
304,432
299,318
253,281
85,995
Operating Income
551,475
551,475
337,574
267,531
275,902
Net Non Operating Interest Income Expense
-18,095
-18,095
-18,762
-16,947
-7,526
Other Income Expense
23,752
23,752
29,517
-1,666
-19,858
Pretax Income
557,132
557,132
348,329
248,918
248,518
Tax Provision
113,041
113,041
66,735
46,789
-154,192
Net Income Common Stockholders
444,091
444,091
281,594
202,129
402,710
Diluted NI Available to Com Stockholders
444,091
444,091
281,594
202,129
402,710
Basic EPS
3.07
3.50
2.13
1.48
2.86
Diluted EPS
3.02
3.43
2.10
1.44
2.74
Basic Average Shares
127,481.75
126,827
131,927
136,844
140,646
Diluted Average Shares
129,916.75
129,424
134,197
140,608
146,796
Total Operating Income as Reported
551,475
551,475
337,574
267,531
275,902
Total Expenses
463,849
463,849
491,679
392,585
167,408
Net Income from Continuing & Discontinued Operation
444,091
444,091
281,594
202,129
402,710
Normalized Income
425,158.28
425,158.28
257,723.60
203,481.79
417,206.34
Interest Expense
18,095
18,095
18,762
16,947
7,526
Net Interest Income
-18,095
-18,095
-18,762
-16,947
-7,526
EBIT
575,227
575,227
367,091
265,865
256,044
EBITDA
656,539
656,539
451,947
315,506
259,041
Reconciled Cost of Revenue
149,154
149,154
181,278
132,811
78,416
Reconciled Depreciation
81,312
81,312
84,856
49,641
2,997
Net Income from Continuing Operation Net Minority Interest
444,091
444,091
281,594
202,129
402,710
Total Unusual Items Excluding Goodwill
23,752
23,752
29,517
-1,666
-19,858
Total Unusual Items
23,752
23,752
29,517
-1,666
-19,858
Normalized EBITDA
632,787
632,787
422,430
317,172
278,899
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
4,819.28
4,819.28
5,646.60
-313.21
-5,361.66
12/31/2021 - 3/16/2004
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
EXEL Exelixis, Inc.
35.31
+2.47%
CPRX Catalyst Pharmaceuticals, Inc.
22.05
+2.80%
ARGX argenx SE
580.94
+6.36%
KRYS Krystal Biotech, Inc.
165.00
+2.71%
HRMY Harmony Biosciences Holdings, Inc.
29.17
+0.62%
BMRN BioMarin Pharmaceutical Inc.
56.82
+0.89%
CORT Corcept Therapeutics Incorporated
68.62
+1.31%
RPRX Royalty Pharma plc
31.95
+2.37%
ADMA ADMA Biologics, Inc.
19.40
+3.85%
TGTX TG Therapeutics, Inc.
36.71
+2.03%